1. Abdalla E.K., Vauthey J.N., Ellis L.M., et al.
Recurrence and outcomes following hepatic resection, radiofrequency ablation,
and combined resection/ablation for colorectal liver metastases. Ann. Surg. 2004; 239:818–825; discussion 825–827.
2. Adam R., Delvart V., Pascal G., et al. Rescue surgery for
unresectable colorectal liver metastases downstaged by chemotherapy: a model to
predict long-term survival. Ann Surg. 2004; 240,644–657.
3. Adam R., Aloia T., Levi F., et al. Hepatic resection
after rescue cetuximab treatment for colorectal liver metastases previously
refractory to conventional systemic therapy. J Clin Oncol. 2007; 25:4593–4602.
4. Adam R., de Haas R.J., Wicherts D.A., et al. Is hepatic resection
justified after chemotherapy in patients with colorectal liver metastases and
lymph node involvement? J. Clin. Oncol. 2008; 26,3672–3680.
5. Adam R., Wicherts D.A., de Haas R.J., et al.
Patients with initially unresectable colorectal liver metastases: is there a
possibility of cure? J Clin Oncol. 2009; 27:1829–1835.
6. Adam R., Bhangui P., Poston G., et al. Is
perioperative chemotherapy useful for solitary, metachronous, colorectal liver
metastases? Ann Surg. 2010; 252:774–787.
7. D'Alessandro A.M., Kalayoglu M., Sollinger H.W., et al. The predictive value
of donor liver biopsies for the development of primary nonfunction after
orthotopic liver transplantation. Transplantation. 1991; 51:157–163.
8. D'Angelica M., Kornprat P., Gonen M., et al. Lack
of evidence for increased operative morbidity after hepatectomy with
perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007; 14:759–765.
9. DeAngelis R.A., Markiewski M.M., Taub R., et al. A
high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression
of the NF-kappaB inhibitor, IkappaBalpha. Hepatology. 2005; 42:1148–1157.
10. Aloia T., Sebagh M., Plasse M., et al. Liver
histology and surgical outcomes after preoperative chemotherapy with
fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006; 24:4983–4990.
11. Altendorf-Hofmann A., Scheele J. A critical review
of the major indicators of prognosis after resection of hepatic metastases from
colorectal carcinoma. Surg. Oncol. Clin. N. Am. 2003; 12,165–192.
12. Auer R.C., White R.R.,Kemeny N.E., et al.
Predictors of a true complete response among disappearing liver metastases from
colorectal cancer after chemotherapy. Cancer. 2010; 116:1502–1509.
13. Aussilhou B., Dokmak S.,
Faivre S., et al. Preoperative liver hypertrophy induced by portal flow
occlusion before major hepatic resection for colorectal metastases can be
impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553–1559.
14. El-Badry A.M.,
Breitenstein S., Jochum W., et al. Assessment of hepatic steatosis by expert
pathologists: the end of a goldstandard. Ann Surg. 2009;250:691–697.
15. Barnett K.T., Malafa M.P. Complications of hepatic
artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer. 2001; 30:147–160.
16. Belghiti J., Hiramatsu K., Benoist S., et al.
Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the
actual risk of liver resection. J Am Coll Surg. 2000; 191:38–46.
17. Benoist S., Brouquet A., Penna C., et al. Complete
response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006; 24:3939–3945.
18. Boige V., Malka D., Elias D., et al. Hepatic
arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver
metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15:219–226.
19. Bokemeyer C., Bondarenko I. ,Makhson A., et al.
Fluorouracil, leucovorin, and oxaliplatin with andwithout cetuximab in the
first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;,27:663–671.
20. Breitenstein S., DeOliveira M.L., Raptis D.A., et
al. Novel and simple preoperative score predicting complications following
liver resection in non-cirrhotic patients. Ann Surg. 2010 ; 252:726–34.
21. Brouquet A.,Benoist S., Julie C., et al. Risk factors
for chemotherapy-associated liver injuries: a multivariate analysis of a group
of 146 patients with colorectal metastases. Surgery. 2009;145:362–371.
22. Capussotti L., Vigano L., Ferrero A. et al. Timing of resection of
liver metastases synchronous to colorectal tumor: proposal of prognosis-based
decisional model. Ann. Surg. Oncol. 2007;14,1143–1150.
23. Carpizo D.R., D'Angelica M. Liver resection for
metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol. 2009; 10,801–809.
24. Carpizo D.R., Are C., Jarnagin W. et al. Liver resection for
metastatic colorectal cancer in patients with concurrent extrahepatic disease:
results in 127 patients treated at a single center. Ann. Surg. Oncol. 2009; 16,2138–2146.
25. Cejas P., Lopez-Gomex M., Aguayo C. et al. KRAS mutation in
primary colorectal cancer tumors and related metastases: A poten tial role in
predicition of lung metastasis. PLoS ONE4,E1899, 2009.
26. Chen M.L., Fang C.H., Liang L.S., et al. A
meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin
compared with fluorouracil/leucovorin in treating advanced colorectal cancer. Surg Oncol. 2010; 19:38–45.
27. Choti M.A., Sitzmann J.V., Tiburi M.F., et al.
Trends in long-term survival following liver resection for hepatic colorectal
metastases. Ann Surg. 2002; 235:759–766.
28. Chun Y.S., Laurent A., Maru D., Vauthey J.N.
Management of chemotherpy-associated hepatotoxicity in colorectal liver
metastases. Lancet Oncol. 2009; 10,278–286.
29. Clavien P.A., Selzner N., Morse M., et al.
Downstaging of hepatocellular carcinoma and liver metastases from colorectal
cancer by selective intra-arterial chemotherapy. Surgery. 2002; 131:433–442.
30. Clavien P.A., Petrowsky H., DeOliveira M.L., et
al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007; 356:1545–1559.
31. Clavien P.A., Oberkofler C.E., Raptis D.A., et al.
What is critical for liver surgery and partial liver transplantation: size or
quality? Hepatology. 2010; 52:715–729.
32. Covey A.M., Brown K.T., Jarnagin W.R., et al.
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment
strategy for resectable hepatic colorectal metastases. Ann Surg. 2008; 247:451–455.
33. Cummings L.C..,Payes J.D..,Coopers G.S. Survival
of the hepatic resection in metastatic colorectal cancer.a population based
study. Cancer. 2007; 109:718-726.
34. Van Cutsem E., Kohne C.H., Hitre E., et al.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal
cancer. N Engl J Med. 2009; 360:1408–1417.
35. Day C.P., James O.F. Hepatic steatosis: innocent
bystander or guilty party? Hepatology. 1998; 27,1463–1466.
36. Delaunoit T., Alberts S.R., Sargent D.J., et al.
Chemotherapy permits resection of metastatic colorectal cancer: experience from
Intergroup N9741. Ann Oncol. 2005;16:425–429.
37. Deleve L.D., Wang X., Tsai J., et al. Sinusoidal
obstruction syndrome (venoocclusive disease) in the rat is prevented by matrix
metalloproteinase inhibition. Gastroenterology. 2003;125:882–890.
38. Drixler T.A., Vogten M.J., Ritchie E.D., et al.
Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg. 2002;.236:703–711;
discuss ion 711–712.
39. Ducreux M., Ychou M., Laplanche A., et al. Hepatic
arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal
cancer with inoperable hepatic metastases: a trial of the gastrointestinal
group of the Federation Nationaledes Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;
23(22):4881–4887.
40. Douillard JY, Cunningham D, Roth AD, et al.
Irinotecan combined with fluorouracil compared with fluorouracil alone as
first-line treatment for metastatic colorectal cancer: a multicentre randomised
trial. Lancet. 2000; 355:1041–1047.
41. Douillard J.Y., Siena S., Cassidy J., et al.
Randomized, phase III trial of panitumumab with infusional
fluorouracil,leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as
first-line treatment in patients with previously untreated metastatic
colorectal cancer: the PRIME study. J ClinOncol. 2010; 28:4697–4705.
42. Elias D., Cavalcanti A., Sabourin J.C. et al. Results of 136
curative hepatectomies with a safety margin of less than 10 mm for colorectal
metastases. J Sur Oncol. 1998; 69,88–93.
43. Elias D., Goere D., Boige V., et al. Outcome of
posthepatectomy-missing colorectal liver metastases after complete response to
chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007; 14:3188–3194.
44. Falcone A., Ricci S., Brunetti I., et al. Phase
III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan
(FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan
(FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo
Oncologico Nord Ovest. JClin Oncol. 2007; 25:1670–1676.
45. Fernandez F.G., Drebin J.A., Linehan D.C., et al.
Five-year survival after resection of hepatic metastases from colorectal cancer
in patients screened by positron emission tomography with F-18
fluorodeoxyglucose (FDG-PET). Ann Surg. 2004; 240:438–447;
discussion 447–450.
46. Feroci F., Fong Y. Use of clinical score to stage
and predict outcome of hepatic resection of metastatic colorectal cancer. J Surg Oncol. 2010; 102:914–921.
47. Figueras J., Torras J., Valls C., et al. Surgical
resection of colorectal liver metastases in patients with expanded indications:
a single center experience with 501 patients. Dis Colon Rect. 2007; 50:
478-488.
48. Floriani I., Torri V., Rulli E. et al. Performance of imaging
modalities in diagnosis of liver metastases from colorectal cancer: a
systematic review and meta-analysis. J. Magn. Reson. Imaging. 2010; 31:19–31.
49. Folprecht G., Gruenberger T., Bechstein W.O. et
al. Tumors response and secondary respectability of colorectal liver metastases
following neoadjuvant chemotherapy with cetuximab: The CELIM randomized phase 2
trial. Lancet Oncol. 2010; 11: 38-47.
50. Fong Y., Fortner J., Sun R.L. et al. Clinical score for
predicting recurrence after hepatic resection for metastatic colorectal cancer,
analysis of 1001 consecutive cases. Ann. Surg. 1999;230:309–321.
51. Fong Y., Bentrem D.J. CASH
(Chemotherapy-Associated Steatohepatitis) costs. Ann Surg. 2006; 243:8–9.
52. Fornaro L., Masi G., Loupakis F., Vasile E.,
Falcone A. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin
Pharmacother. 2010; 11,63–77.
53. Giacchetti S., Perpoint B., Zidani R., et al.
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated
fluorouracil-leucovorin as first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 2000; 18:136–147.
54. Giraudo G., Greget M., Oussoultzoglou E., et al.
Preoperative contralateral portal vein embolization before major hepatic
resection is a safe and efficient procedure: a large single institution
experience. Surgery. 2008; 143:476–482.
55. Goere D., Farges O., Leporrier J., et al.
Chemotherapy does not impair hypertrophy of the left liver after right portal
vein obstruction. J Gastrointest Surg. 2006; 10:365–370.
56. Goere D., Deshaies I., de Baere T., et al.
Prolonged survival of initially unresectable hepatic colorectal cancer patients
treated with hepatic arterial infusion of oxaliplatin followed by radical
surgery of metastases. Ann Surg. 2010; 251:686–691.
57. Goshen E., Davidson T., Zwas S.T. et al. PET/CT in the
evaluation of response to treatment of liver metastases from colorectal cancer
with bevacizumab and irinotecan. Technol. Cancer Res. Treat 2006; 5:37–43.
58. de Gramont A., Figer A., Seymour M., et al.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment
in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938–2947.
59. Grand D.J., Beland M., Noto R.B., Mayo-Smith W.
Optimum imaging of colorectal metastases. J Surg
Oncol.2010; 102:909–913.
60. Grivicich I., Regner A., da Rocha A.B. et al. The
irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese
superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy. 2005;.51,93–102.
61. Gruenberger B., Tamandl D., Schueller J., et al.
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients
with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008; 26:1830–1835.
62. de Haas R.J., Wicherts D.A., Adam R. Resection of
colorectal liver metastases with extrahepatic disease. Dig Surg 2008; 25:461– 466.
63. Hecht J.R , Mitchell E., Chidiac T., et al. A
randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab
compared with chemotherapy and bevacizumab alone for metastatic colorectal
cancer. J Clin Oncol. 2009; 27:672– 680.
64. Hagspiel K.D., Neidl K.F.W., Eicheberger A.C. et al. Detection of liver
metastases: comparison of superparamagnetic iron oxide- enhanced and unenhanced
MR imaging at 1.5 T with dynamic CT, intraoperative US and percutaneous US. Radiology 1995;
196:471–478.
65. Hutchins G., Southward K., Handley K. et al. Value of mismatch
repair, KRAS, and BRAF mutations in predicting recurrence and benefits from
chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261–1270.
66. Jaeck D., Nakano H., Bachellier P. et al. Significance of
hepatic pedicle lymph node involvement in patients with colorectal liver
metastases: a prospective study. Ann Surg. Oncol . 2002; 9:430–438.
67. Jaeck D., Oussoultzoglou E., Rosso E., et al. A
two-stage hepatectomy procedure co mbined with portal vein embolization to
achieve curative resection for initially unresectable multiple and bilobar
colorectal liver metastases. Ann Surg. 2004; 240:1037–1049;
discussion 1049–1051.
68. Iwatsuki S., Dvorcic I., Madariaga J.R., et al.
Hepatic resecrion for metastatic colorectal adenocarcinoma: a proposal of a
prognostic scoring system. J Am Coll Surg 1999; 159:291-299.
69. Kato T., Yasui K., Hirai T. et al. Therapeutic results
for hepatic metastasis of colorectal cancer with special reference to
effectiveness of hepatectomy: analysis of prognostic factors for 763 cases
recorded at 18 institutions. Dis. Colon Rectum 2003; 46(Suppl.
10),S22–S31.
70. Kemeny N., Daly J., Reichman B., et al. Intrahepatic
or systemic infusion of fluorodeoxyuridine in patients with liver metastases
from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;
107(4):459–465.
71. Kesmodel S.B., Ellis L.M., Lin E., et al.
Preoperative bevacizumab does not significantly increase postoperative
complication rates in patients undergoing hepatic surgery for colorectal cancer
liver metastases. J Clin Oncol. 2008; 26:5254–5260.
72. Khatri V.P., Petrelli N.J., Belghiti J. Extending
the frontiers of surgical therapy for hepatic colorectal metastases: is there a
limit? J Clin Oncol. 2005; 23:8490–8499.
73. Khatri V.P., Chee K.G., Petrelli N.J. Modern
multimodality approach to hepatic colorectal metastases: solutions and
controversies. Surg
Oncol. 2007; 16:71–83.
74. Kingham T.P., D'Angelica M., Kemeny N.E. Role of
intra-arterial hepatic chemotherapy in the treatment of colorectal
cancermetastases. J Surg
Oncol. 2010; 102:988–995.
75. Kishi Y., Zorzi D., Contreras C.M., et al.
Extended preoperative chemotherapy does not improve pathologic response and
increases postoperative liver insufficiency after hepatic resection for
colorectal liver metastases. Ann Surg Oncol. 2010; 17:2870–6.
76. Kneuertz P.J., Maithel S.K., Staley C.A., Kooby
D.A. Chemotherapy-associated liver injury: impact on surgical management of colorectal
cancer liver metastases. Ann. Surg.
Oncol. 2011; 18:181–190.
77. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in
metastatic colorectal cancer is associated with adoption of hepatic resection
and improved chemotherapy. J. Clin. Oncol. 2009; 27:3677–3683.
78. Langer B., Bleiberg H.,
Labianca R., et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus
observation after potentially curative resection of liver or lung metastases
from colorectal cancer (CRC): results of the ENG (EORTC/NCICCTG/GIVIO)
randomized trial. Proc. Am. Soc. Clin. Oncol. 2002; 21:149a (Abstract 592).
79. Loupakis F., Falcone A.
Chemotherapy. How useful is adjuvant irinotecan in stage IV CRC? Nat Rev Clin Oncol. 2010; 7:190– 191.
80. Mahfud M., Breitenstein S., El-Badry A.M., et al.
Impact of preoperative bevacizumab on complications after resection of
colorectal liver metastases: case-matched control study. World J Surg. 2010 ;34:92–100.
81. Mainenti P.P., Mancini M.,
Mainolfi C., et al. Detection of colo-rectal liver metastases: prospective
comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR
with extracellular and reticulo-endothelial cell specific contrast agents. Abdom. .
Imaging. 2010; 35:511–521.
82. Manfredi S., Lepage C.,
Hatem C., et al. Epidemiology and management of liver metastases from
colorectal cancer. Ann Surg. 2006; 244:254–259.
83. Masi G., Loupakis F.,
Pollina L., et al. Long-term outcome of initially unresectable metastatic
colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin
and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg, 2009; 249 : 420–425.
84. Masi G., Loupakis F.,
Salvatore L. et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil,
and folinate) as first-line treatment for metastatic colorectal cancer: a Phase
2trial. Lancet Oncol. 2010;11:845–852.
85. Mentha G., Terraz S.,
Morel P., et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for
colorectal liver metastases. Br J Surg. 2009; 96:95–103
86. Mocellin S., Pilati P.,
Lise M., et al. Meta-analysis of hepatic arterial infusion for unresectable
liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007; 25:5649–5654.
87. Morris-Stiff G., Tan Y.M.,
Vauthey J.N. Hepatic complications following preoperative chemotherapy with
oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg
Oncol. 2008; 34:609–614.
88. Maughan T.S., Adams R.,
Smith C.G., et al. Identification of potentially responsive subsets when
cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in
first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN
trial. J Clin Oncol (Meeting
Abstracts). 2010; 28(15_suppl):3502.
89. Nakano H., Oussoultzoglou
E., Rosso E., et al. Sinusoidal injury increases morbidity after major
hepatectomy in patients with colorectal liver metastases receiving preoperative
chemotherapy. Ann Surg. 2008; 247:118–124.
90. Nash G.M., Gimbel M., Shia J. et al. KRAS mutation correlates
with accelerated metastatic progression in patients with colorectal liver
metastases. Ann. Surg. Oncol. 2010;17:572–578.
91. Niekel M.C., Bipat S.,
Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR
imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including
patients who have not previously undergone treatment..Radiology 2010; 257:674–684.
92. Nordlinger B., Sorbye H.,
Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus
surgery alone for resectable liver metastases from colorectal cancer (EORTC
Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371
(9617):1007–1016.
93. Oussoultzoglou E., Romain
B., Panaro F., et al. Long-term survival after liver resection for colorectal
liver metastases inpatients with hepatic pedicle lymph nodes involvement in the
era of new chemotherapy regimens. Ann Surg. 2009; 249:879–886.
94. Overman M.J., Maru D.M.,
Charnsangavej C., et al. Oxaliplatin-mediated increase in Spleen size as a
biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010; 28:2549–2555.
95. Patel S., McCall M.,
Ohinmaa A. et al. Positron emission tomography/computed Tomography scans
compared to computed tomographic scans for detecting colorectal liver
metastases: a systematic review. Ann Surg. 2011; 253:666–671.
96. Pawlik T.M., Scoggins
C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of
recurrence after hepatic resection for colorectal metastase Ann Surg. 2005;241: 715–722,
discussion 722–724.
97. Pawlik T.M., Olino K.,
Gleisner A.L. et al. Preoperative chemotherapy for colorectal liver metastases:
impact on hepatichistology and postoperative outcome. J Gastrointest Surg. 2007;11:860–868.
98. Pawlik T.M., Assumpcao L.,
Vossen J.A. et al. Trends in nontherapeutic laparotomy rates in patients
undergoing surgical therapy for hepatic colorectal metastases timothy. Ann Surg Oncol. 2009;16:371–378.
99. Piessevaux H. Early tumor
shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal
cancer (MCRC): Analysis from the CRYSTAL study. ESMO abstract 596P. 2010.
100. Portier G., Elias D.,
Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and
folinic acid compared with surgery alone after resection of colorectal liver metastases:FFCD
ACHBTH AURC 9002 trial. J Clin Oncol.2006; 24:4976–4982.
101. Power D.G., Kemeny N.E.
Role of adjuvant therapy after resection of colorectal cancer Liver metastases.
J. Clin.Oncol. 2010; 28:2300–2309.
102. Quaia E., D'Onofrio M.,
Palumob A. et al. Comparison of contrast-enhanced ultrasonography versus
baseline ultrasound and contrast-enhanced computed tomography in metastatic
disease of the liver: diagnostic performance and confidence. Eur Radiol. 2006; 16:1599–1609.
103. Reddy S.K., Morse M.A., Hurwitz H.I., et al.
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative
chemotherapy regimens does not increase morbidity after resection of colorectal
liver metastases. J Am Coll Surg. 2008; 206:96–106.
104. Reddy S.K., Zorzi D., Lum Y.W., et al. Timing of
multimodality therapy for resectable synchronous colorectal liver metastases: a
retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16:1809–1819.
105. Rees M., Tekkis P.P., Welsh F.K., et al.
Evaluation of long-term survival after hepatic resection for metastatic
colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 24:125–135.
106. Reissfelder C., Rahbari N.N., Koch M. et al. Validation of
prognostic scoring systems for patients undergoing resection of colorectal
cancer liver metastases. Ann Surg Oncol. 2009; 16:3279–3288.
107. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves
pathologic response and protects against hepatic injury in patients treated
with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007; 110:2761–2767.
108. Richman S.D., Seymour M.T., Chambers P et al. KRAS and BRAF mutations in advanced
colorectal cancer are associated with poor prognosis but do not preclude benefit
from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27:5931–5937.
109. Rojas Llimpe F., Di Fabio F., Ercolani G., et al. Presurgical
comparative imaging evaluation in patients with colorectal cancer liver
metastasis (PROMETEO Study). Presented at: 2009 ASCO Annual
Meeting. Orlando, FL, USA, 29 May–2 June2009.
110. De Roock W., Jonker D.J., Di Nicolantonio F., et
al. Association of KRAS p. G13D mutation with outcome in patients with
chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304:1812–1820.
111. De Roock W., Claes B., Bernasconi D., et al.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab
plus chemotherapy in chemotherapy- Refractory metastatic colorectal cancer: a
retrospective consortium analysis. Lancet Oncol. 2010; 11:753–762.
112. Roth A.D., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: results of the translational study on the PETACC-3,
EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28:466–474.
113. Rubbia-Brandt L., Audard V., Sartoretti P., et
al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based
chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466.
114. Rubbia-Brandt L., Lauwers G.Y., Wang H., et al.
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are
frequent oxaliplatin-associated liver lesions and partially prevented by
bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010; 56:430–439.
115. Ryan P., Nanji S., Pollett A., et al.
Chemotherapy-induced liver injury in metastatic colorectal cancer:
semiquantitative histologic analysis of 334 resected liver specimens shows that
vascular injury but not steatohepatitis is associated with preoperative
chemotherapy. Am J Surg Pathol. 2010; 34:784–791.
116. Saltz L.B., Cox J.V., Blanke C., et al.
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Irinotecan Study Group. N Engl J Med. 2000; 343:905–914.
117. Saltz L.B., Clarke S., Diaz-Rubio E., et al.
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line
therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013–2019.
118. Sahani D.V., Kalva S.P.,
Tanabe K.K., et al. Intraoperative US in patients undergoing surgery for
liver neoplasms: comparison with MR imaging. Radiology 2004; 232:810–814.
119. de Santibañes E.,
Fernandez D., Vaccaro C., et al. Short-term and long-term
outcomes after simultaneous resection of colorectal malignancies and
synchronous liver metastases. World J Surg. 2010; 34:2133–2140.
120. Scappaticci F.A.,
Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in
metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91:173–180.
121. Selzner N., Pestalozzi
B.C., Kadry Z., et al. Downstaging colorectal liver metastases by concomitant
unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg. 2006; 93:587–592.
122. Soubrane O., Brouquet A.,
Zalinski S., et al. Predicting high grade lesions of sinusoidal obstruction
syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases:
correlation with post-hepatectomy outcome. Ann Surg.2010; 251:454–460.
123. Steele G Jr, Ravikumar
TS. Resection of hepatic metastases from colorectal cancer. Biologic
perspective. Ann Surg. 1989; 210:127–138.
124. Strasberg S.M., Dehdashti
F. Role of FDG-PET staging in selecting the optimum patient for hepatic
resection of metastatic colorectal cancer. J. Surg. Oncol. 2010; 102:955–959.
125. Tabernero J., Van Cutsem
E., Diaz-Rubio E., et al. Phase II trial of cetuximab in combination with
fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 2007; 25:5225–5232.
126. Takamoto T., Hashimoto
T., Sano K., et al. Recovery of liver function after the cessation of preoperative
chemotherapy for colorectal liver metastasis. Ann Surg Oncol. 2010; 17:2747–2755.
127. Tan M.C., Linehan D.C.,
Hawkins W.G. et al. Chemotherapy-induced normalization of FDG uptake by
colorectal liver metastases does not usually indicate complete pathologic response.
J Gastrointes Surg. 2007; 11:1112–1119.
128. Tamandl D, Gruenberger B,
Klinger M, et al. Liver resection remains a safe procedure after neoadjuvant
chemotherapy including bevacizumab: a case-controlled study. Ann Surg. 2010; 252:124–130.
129. Tanaka K., Shimada H.,
Ueda M., et al. Perioperative complications after hepatectomy with or without
intra-arterial chemotherapy for bilobar colorectal cancer liver metastases. Surgery. 2006; 139:599–607.
130. Taniguchi E., Sakisaka
S., Matsuo K., et al. Expression and role of vascular endothelial growth factor
in liver regeneration after partial hepatectomy in rats. J Histochem
Cytochem. 2001; 49:121–130.
131. Taylor I. Adjuvant
chemotherapy after resection of liver metastases from colorectal cancer. Eur. J. Cancer 2008; 44,1198–1201.
132. Teli M.R., James O.F.,
Burt A.D. et al. The natural history of nonalcoholic fatty liver: a
follow-up study. Hepatology 1995; 22:1714–1719.
133. Tie J., Lipton L., Desai
J. et al. KRAS mutation is associated with lung metastasis in
patients with curatively resected colorectal cancer. Clin. Cancer
Res. 2011; 17:1122–1130.
134. Tol J., Koopman M., Cats
A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 2009; 360:563–572.
135. Tomlinson J.S., Jarnagin
W.R., DeMatteo R.P. et al. Actual 10-year survival after resection of colorectal
liver metastases defines cure. J. Clin. Oncol. 2007; 25:4575–4580.
136. Vauthey J.N., Pawlik
T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an
increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24:2065–2072.
137. Vauthey J.N., Choti M.A.,
Helton W.S. AHPBA/SSO/SSAT consensus conference on hepatic colorectal
metastases: rationale and overview of the conference. Ann Surg Oncol.
2006;
13:1259–1260.
138. Weber S.M., Jarnagin
W.R., DeMatteo R.P., et al. Survival after resection of multiple hepatic
colorectal metastases. Ann Surg Oncol. 2000; 7:643–650.
139. Welsh F.K., Tilney H.S.,
Tekkis P.P., et al. Safe liver resection following chemotherapy for colorectal
metastases is a matter of timing. Br J Cancer. 2007; 96:1037–1042.
140. Wernecke K., Rummeny E.,
Bongartz G., et al. Detection of hepatic masses in patients with
carcinoma: comparative sensitivities of sonography, CT, and MR imaging. Am. J. Roentgenol.1991; 157:731–739.
141. Wildi S.M., Gubler C.,
Hany T., et al. Intraoperative sonography in patients with colorectal cancer
and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound. 2008; 36:20–26.
142. Wilson S.R., Greenbaum
L.D., Goldberg B.B. Contrast-enhanced ultrasound: what is the evidence and what
are the obstacles? Am J Roentgenol. 2009; 193:55–60.
143. Ychou M., Hohenberger W.,
Thezenas S., et al. A randomized Phase III study comparing adjuvant
5-fluorouracil/folinic acid with FOLFIRI in patients following complete
resection of liver metastases from colorectal cancer. Ann. Oncol. 2009; 20:1964–1970.
144. Zorzi D., Laurent A.,
Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for
colorectal liver metastases. Br J Surg. 2007; 94:274–286.
145. Zorzi D., Chun
Y.S., Madoff D.C., et al. Chemotherapy with bevacizumab does not affect liver
regeneration after portal vein embolization in the treatment of colorectal
liver metastases. Ann Surg Oncol. 2008; 15:2765–2772.
